Filing Flows › Tandem Diabetes Care (TNDM) › Q3 2026
Tandem Diabetes Care (TNDM) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Tandem Diabetes Care (TNDM) reported revenue of $284M for the third quarter 2026 (Q3 2026), +14% from a year earlier and +11% from the quarter before. Operating margin was -0.8%, net loss $7.1M (2.5% of revenue).
Tandem Diabetes Care, Q3 2026: revenue $284M (+14% year over year), operating margin -0.8%, net loss $7.1M, operating cash flow −$819K. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $284M | +11% | +14% |
| Operating profit | −$2.4M | — | — |
| Net earnings | −$7.1M | — | — |
| Operating cash flow | −$819K | — | -110% |
What changed
Revenue was $283.7M in Q3 2026, up 14% year over year and up 11% from the previous quarter. Supplies and other was the largest line at 59% of revenue. Supplies and other added $29.6M year over year (up 21%), 86% of the total change.
Gross margin was 56.5%, up 2.7 points from Q3 2025. Operating costs exceeded revenue by $2.4M, an operating margin of -0.8%. Operating expenses grew 4% against revenue growth of 14%. The quarter ended with a net loss of $7.1M, narrower than the previous quarter's $21.2M loss. Net interest and other expense of $5.3M was the main reason.
Operating cash flow was −$819K. Non-cash charges added back $4.5M of depreciation and amortization and $15.9M of share-based compensation. Working capital and other items used $14.1M. Capital expenditures of $4.7M exceeded it, leaving free cash flow of −$5.5M.
Questions
What was Tandem Diabetes Care's revenue in the third quarter 2026?
Tandem Diabetes Care (TNDM) reported revenue of $284M for the third quarter 2026 (Q3 2026), +14% from a year earlier and +11% from the quarter before.
Was Tandem Diabetes Care profitable in the third quarter 2026?
Operating loss was $2.4M (-0.8% of revenue) and net loss $7.1M.